Related references
Note: Only part of the references are listed.STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Carminia M. Della Corte et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway
Priya S. Dalvi et al.
MOLECULAR CANCER RESEARCH (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array
Georgina Mansell et al.
BMC GENOMICS (2019)
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi et al.
NATURE (2019)
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Junko Murai et al.
PHARMACOLOGY & THERAPEUTICS (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer
Marcel A. Dammed et al.
NATURE COMMUNICATIONS (2019)
Correlation Patterns Between DNA Methylation and Gene Expression in The Cancer Genome Atlas
John C. G. Spainhour et al.
CANCER INFORMATICS (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?
Dmitriy Sonkin et al.
LUNG CANCER MANAGEMENT (2019)
Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
Sai-Wen Tang et al.
CLINICAL CANCER RESEARCH (2018)
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Yu-Han Huang et al.
GENES & DEVELOPMENT (2018)
Identifying a missing lineage driver in a subset of lung neuroendocrine tumors
Karine Pozo et al.
GENES & DEVELOPMENT (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer
Tuo Li et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
The association between copy number aberration, DNA methylation and gene expression in tumor samples
Wei Sun et al.
NUCLEIC ACIDS RESEARCH (2018)
Identifying a missing lineage driver in a subset of lung neuroendocrine tumors (vol 32, pg 865, 2018)
Karine Pozo et al.
GENES & DEVELOPMENT (2018)
The functional diversity of Aurora kinases: a comprehensive review
Estelle Willems et al.
CELL DIVISION (2018)
Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
Jung Wook Park et al.
SCIENCE (2018)
The NCI-60 Methylome and Its Integration into CellMiner
William C. Reinhold et al.
CANCER RESEARCH (2017)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1
Erkin Erdal et al.
GENES & DEVELOPMENT (2017)
Immune Diseases Associated with TREX1 and STING Dysfunction
Nan Yan
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2017)
Telomeres in cancer: tumour suppression and genome instability
John Maciejowski et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer
Tao He et al.
EPIGENOMICS (2017)
Aurora kinases: novel therapy targets in cancers
Anqun Tang et al.
ONCOTARGET (2017)
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
C. Allison Stewart et al.
ONCOTARGET (2017)
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
Beverly A. Teicher et al.
CANCER MEDICINE (2017)
Small-cell lung cancer: what we know, what we need to know and the path forward
Adi F. Gazdar et al.
NATURE REVIEWS CANCER (2017)
Family matters: How MYC family oncogenes impact small cell lung cancer
Johannes Braegelmann et al.
CELL CYCLE (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Vanesa Nogales et al.
ONCOTARGET (2016)
YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer
Masafumi Horie et al.
CANCER SCIENCE (2016)
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio et al.
CELL (2016)
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
Eric Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Small cell lung cancer: Time to revisit DNA-damaging chemotherapy
Anish Thomas et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
Eric Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Chromothripsis and Kataegis Induced by Telomere Crisis
John Maciejowski et al.
CELL (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
J. T. Poirier et al.
ONCOGENE (2015)
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
Timothy J. Stuhlmiller et al.
CELL REPORTS (2015)
Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays
Martin J. Aryee et al.
BIOINFORMATICS (2014)
The 3′-5′ DNA Exonuclease TREX1 Directly Interacts with Poly(ADP-ribose) Polymerase-1 (PARP1) during the DNA Damage Response
Takuya Miyazaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters
Alexandra Naba et al.
ELIFE (2014)
Poised epigenetic states and acquired drug resistance in cancer
Robert Brown et al.
NATURE REVIEWS CANCER (2014)
O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer
Joerg Fahrer et al.
CARCINOGENESIS (2013)
The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells
S. Kalari et al.
ONCOGENE (2013)
Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis
Toshiyuki Minami et al.
SCIENTIFIC REPORTS (2013)
IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data
Dan Wang et al.
BIOINFORMATICS (2012)
The sva package for removing batch effects and other unwanted variation in high-throughput experiments
Jeffrey T. Leek et al.
BIOINFORMATICS (2012)
HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter-Mediated Chemoresistance in Small Cell Lung Cancer
Toshiyuki Minami et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
DNA methylation profiling in the clinic: applications and challenges
Holger Heyn et al.
NATURE REVIEWS GENETICS (2012)
Microtubule plus-ends within a mitotic cell are 'moving platforms' with anchoring, signalling and force-coupling roles
Naoka Tamura et al.
OPEN BIOLOGY (2012)
Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families
Keith B. Glaser et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Epigenome-wide association studies for common human diseases
Vardhman K. Rakyan et al.
NATURE REVIEWS GENETICS (2011)
EB1 Is Required for Spindle Symmetry in Mammalian Mitosis
Anke Bruening-Richardson et al.
PLOS ONE (2011)
Uncovering new substrates for Aurora A kinase
Teresa Sardon et al.
EMBO REPORTS (2010)
A small-cell lung cancer genome with complex signatures of tobacco exposure
Erin D. Pleasance et al.
NATURE (2010)
Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage
Markus Christmann et al.
NUCLEIC ACIDS RESEARCH (2010)
TREX1 acts in degrading damaged DNA from drug-treated tumor cells
Chuan-Jen Wang et al.
DNA REPAIR (2009)
A Gene-Alteration Profile of Human Lung Cancer Cell Lines
Raquel Blanco et al.
HUMAN MUTATION (2009)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer
Z. Zhang et al.
ONCOGENE (2006)
Melanophilin and myosin Va track the microtubule plus end on EB1
XS Wu et al.
JOURNAL OF CELL BIOLOGY (2005)
Importance of Sp1 consensus motifs in the MYCN promoter
TH Inge et al.
SURGERY (2002)
Share Paper
